ROCKVILLE, Md., April 17, 2019 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq: RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced the appointment of Steve Pakola, M.D., as its Senior Vice President
and Chief Medical Officer. Dr. Pakola will report to Kenneth T. Mills, REGENXBIO's President and
Chief Executive Officer.
Dr. Pakola joins REGENXBIO from Aerpio Pharmaceuticals, Inc.,
where he was Chief Medical Officer. He has held key leadership
roles in preclinical and clinical development, regulatory affairs
and medical affairs. While Dr. Pakola's therapeutic area experience
encompasses multiple indications, his predominant focus has been
the development of treatments for retinal disorders, including
clinical development experience in diabetic retinopathy, diabetic
macular edema and age-related macular degeneration (AMD). He was
the lead inventor and program lead for the Jetrea®
(ocriplasmin) program, from inception in 2002 through the therapy's
United States and European
regulatory submissions in 2012.
"In this role, Steve will leverage his rich industry experience
and expertise in the discovery and development of novel treatments
for retinal disease," said Mr. Mills. "Steve's background as an
innovator in drug development is particularly relevant as we
leverage our breakthrough science to advance five current
proprietary therapeutic programs that focus on retinal,
neurodegenerative and metabolic diseases. We are excited to welcome
Steve to the team."
"I am thrilled to join REGENXBIO at this time of exciting
momentum for the company as it advances the development of gene
therapies," said Dr. Pakola. "REGENXBIO's NAV Technology Platform
has the potential to transform the course of treatment for patients
with rare diseases as well as in broader applications such as wet
AMD. I look forward to working with my colleagues, investigators
and the regulatory authorities to bring new and innovative
treatments to patients."
Prior to Aerpio, Dr. Pakola served as Chief Medical Officer at
Amakem NV and as Senior Vice President and Chief Medical Officer at
ThromboGenics NV. Earlier in his career, Dr. Pakola served as
Associate Director of Cardiovascular Clinical Research at
Boehringer Ingelheim, where he was Global Medical Lead on the
Lipid-Lowering Development Programme and the USA Medical Lead for the Direct Thrombin
Inhibitor Development Programme. Prior to that, Dr. Pakola served
in senior-level clinical development positions at Quintiles
Cardiovascular Therapeutics and at Organon.
Dr. Pakola earned a B.A., summa cum laude, and an M.D.
from the University of Pennsylvania,
where he was elected to the Alpha Omega Alpha Honor Medical
Society.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "design," "intend,"
"expect," "could," "plan," "potential," "predict," "seek,"
"should," "would" or by variations of such words or by similar
expressions. The forward-looking statements include statements
relating to, among other things, REGENXBIO's future operations and
clinical trials. REGENXBIO has based these forward-looking
statements on its current expectations and assumptions and analyses
made by REGENXBIO in light of its experience and its perception of
historical trends, current conditions and expected future
developments, as well as other factors REGENXBIO believes are
appropriate under the circumstances. However, whether actual
results and developments will conform with REGENXBIO's expectations
and predictions is subject to a number of risks and uncertainties,
including the timing of enrollment, commencement and completion and
the success of clinical trials conducted by REGENXBIO, its
licensees and its partners, the timing of commencement and
completion and the success of preclinical studies conducted by
REGENXBIO and its development partners, the timely development and
launch of new products, the ability to obtain and maintain
regulatory approval of product candidates, the ability to obtain
and maintain intellectual property protection for product
candidates and technology, trends and challenges in the business
and markets in which REGENXBIO operates, the size and growth of
potential markets for product candidates and the ability to serve
those markets, the rate and degree of acceptance of product
candidates, and other factors, many of which are beyond the control
of REGENXBIO. Refer to the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" sections of REGENXBIO's Annual Report on Form 10-K for
the year ended December 31, 2018 and
comparable "risk factors" sections of REGENXBIO's Quarterly Reports
on Form 10-Q and other filings, which have been filed with the U.S.
Securities and Exchange Commission (SEC) and are available on the
SEC's website at www.sec.gov. All of the forward-looking statements
made in this press release are expressly qualified by the
cautionary statements contained or referred to herein. The actual
results or developments anticipated may not be realized or, even if
substantially realized, they may not have the expected consequences
to or effects on REGENXBIO or its businesses or operations. Such
statements are not guarantees of future performance and actual
results or developments may differ materially from those projected
in the forward-looking statements. Readers are cautioned not to
rely too heavily on the forward-looking statements contained in
this press release. These forward-looking statements speak only as
of the date of this press release. REGENXBIO does not undertake any
obligation, and specifically declines any obligation, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contacts:
Investors:
Heather Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-appoints-dr-steve-pakola-as-chief-medical-officer-300833120.html
SOURCE REGENXBIO Inc.